About Galera - Galera Therapeutics, Inc.

Galera develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors.

Superoxide Dismutase Mimetics
Excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera’s SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advanced breast cancer.

Nitric Oxide Synthase Inhibitors
Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion. Galera’s tilarginine (L-NMMA) inhibits NO production, showing promise in combination with taxane chemotherapy for resistant breast cancer. It is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer.

"As a medical oncologist, few things are more rewarding than contributing to therapies that alleviate patient suffering and enhance quality of life. For more than a decade, we at Galera have been committed to pioneering innovative approaches that reduce the toxicities of cancer therapies. More recently, we have been focused on improving cancer therapies directly, by controlling cancer. Our unwavering focus remains on one vital mission: advancing patient care by easing suffering and elevating quality of life."